Sito in Italia dove è possibile acquistare la consegna acquisto Viagra a buon mercato e di alta qualità in ogni parte del mondo.

Rusnano_corporate_presentation

Business and Financial Partner
PLEASE, CAREFULLY READ THE TEXT BELOW
This document has been prepared by Rusnano, for information purposes only. This document is an indicative summary of the terms and conditions of the securities/transaction described herein and may be amended, superseded or replaced without notice. The conditions of the securities/transaction will be set out in full in the applicable binding transaction document(s). This document shall not constitute an offer of financing, an offer to sell, or the solicitation of an offer to buy or sell any securities described herein, which shall be subject to Rusnano’s internal approvals. Rusnano is acting solely as principal and not as advisor or fiduciary. You must independently determine, with your own advisors, the appropriateness of the securities / transaction before acting. Rusnano accepts no liability whatsoever for any direct or consequential losses arising from the use of this document or reliance on the information contained herein. Rusnano does not guarantee the accuracy or completeness of information which is contained in this document and which is stated to have been obtained from or is based upon trade and statistical services or other third party sources. All opinions and estimates are given as of the date hereof and are subject to change. The value of any investment may fluctuate as a result of market changes. The information in this document is not intended to predict actual results and no assurances are given with respect thereto. Rusnano, its affiliates and the individuals associated therewith may (in various capacities) have positions or deal in transactions or securities (or related derivatives) identical or similar to those described herein. THIS DOCUMENT DOES NOT DISCLOSE ALL THE RISKS AND OTHER ISSUES RELATED TO AN INVESTMENT IN THE SECURITIES/TRANSACTION. PRIOR TO TRANSACTING, YOU SHOULD ENSURE THAT YOU FULLY UNDERSTAND THE TERMS OF THE SECURITIES/TRANSACTION AND ANY RISKS. YOU SHOULD ACT ON THE BASIS OF INFORMATION IN THE BINDING TRANSACTION DOCUMENT(S) AND NOT ON THE BASIS OF ANY INFORMATION PROVIDED HEREIN. 10th largest economy in the world by nominal GDP Nominal GDP, $ bln
and the 6th largest by purchasing power parity • Economy of Russia will grow faster than the World’s economy with high oil prices and investments being • > 140mn in population, 75 mn of educated labor force and high consumer spending as % of GDP • Diversified base in fundamental research with strong Source: Global Intelligence Unit
support from government: Russian Academy of Real consumer spending growth, %
Science (RAS) is the leading science organization in Russia with 466 research institutes and 55 000 researchers (61% of researchers with Ph.D. degree) Source: Global Intelligence Unit
Established in 2007 to implement National policy of innovative economic development
Invested over $XX bn in XX projects
Our Priority
Our Profile
Our Capabilities
We apply flexible investment approach, giving our portfolio companies strong financial
and administrative support
Financing
Governing
Investment
Requirements
By ‘nanotechnology’ we mean a set of methods used in examination, engineering, production and application of structures,
devices, and systems including task-specific control and modification of the shape, size, integration and interaction of single
nano-scale components thereof (with typical size of 100 nm and less), the presence of which defines key features and
properties of a product.

INDUSTRY EXAMPLES
Microelectronics
Air-space technologies
• Classical silicon based• Printed electronics Medical tech
• Membranes for plasma filtration
• Sensors etc.
LED, OLED
Other Areas
• Nuclear technologies (proton therapy, neutron tech.)
Energy storage
• Raw materials for nanotechnologies, instruments, • Li-Ion accumulators, ultra-capacitors RUSNANO is active across entire nanotechnology-related value chain
Intermediate
Nano-scaled
Finished goods
products with
structures in
incorporating
nano-scaled
unprocessed form
nanotechnology
features
Equipment and software used to
visualize, manipulate, and model
objects/processes at nano scale

• Founders / management do not loose control over the business, as RUSNANO holds Financial
• Due to its strategic mandate, RUSNANO is in the unique position to provide long-term and flexible financing aimed at set up and development of nano-production in Russia • Cooperation with the Russian Government, local authorities and leading industry majors helps to overcome any possible administrative barriers on federal and regional levels to administrative
succeed perspective joint projects engaged into production start ups and promotion of nano-products onto Russian and international markets • Facilitating marketing and sales in the local market, assistance in initiation and stimulation of demand on joint project products through a widespread network of the promotion
largest Russian companies and other channels in order to penetrate attractive market and utilize its considerable potential • Operational efficiency improvement due to optimization of funding, transportation, tax, energy and personnel costs resulted from the most favorable production site location at advantages
• Ensuring smooth and fast licensing and other compliance with local legislation Project review process in RUSNANO consists of two major stages –
scientific and technological review and investment valuation

Scientific and technological review
Entry Review
Technical Review
Technical Approval
Investment evaluation
Investment Expertise
Preliminary Approval
Decision Making
RUSNANO uses wide range of instruments including attractive terms
of equity financing along with various types of debt financing

Equity Financing
Debt Financing
Other Instruments
interest payments and 2 years for principal RUSNANO supports generally applicable term sheet concepts with the
only requirement for the production facility to be located in Russia

• Production facility should be located in Russia Jurisdiction
• Project might be structured in compliance with the Russian or foreign law • Equity capital may be formed by cash contributions, IP and tangible assets Share Capital
• RUSNANO’s stake in equity capital should not exceed 50% - 1 share • RUSNANO supports generally applicable term sheet concepts - put/call options, Protection
tag-along, drag-along, anti-dilution, right of first refusal and other concepts • Corporate management from RUSNANO side is executed through the Board of Deal structure*
* Sample deal structure, other options are possible As of end of May 2010 RUSNANO has approved 107 investments projects
Distribution of investments by industry, $ bln
nanomaterials, nanophotonics and medicine which together account for • Funded 35 projects in total amount of Microelectronics (France)Deal size: > $500 mn Composite materials production (prepregs) Projects with Korean Companies in Pipeline Acquisition of stake in supercapacitor producer
JV with producer of OLED equipment
Investments from Rusnano: $30 mn
Investments from Rusnano: $125 mn
Venture fund with 360ip and KIAT
Flash cards production
• 360ip is a leading venture fund in Asia • Commitments from Rusnano: $50 mn
Investments from Rusnano: $115 mn
THANK YOU!
Georgy KolpachevManaging Director+7.495.988.53.88 ext.1559 Georgy.Kolpachev@rusnano.com Dmitry GavvaSenior investment manager +7.495.988.53.88 ext.1719 Dmitry.Gavva@rusnano.com

Source: http://kotra.n4.biz/documents/615529/617240/RUSNANO.pdf

Section:

MATERIAL SAFETY DATA SHEET SECTION: 1.1 PRODUCT IDENTIFICATION Product Name: R osehip Carrier Oil - Organic Botanical Name: Synonyms: Rosa bakeri , Rosa canina var. bakeri , Rosa lutetiana Léman Rosa montivaga, Rosa mosqueta, Rosa rubiginosa INCI Name: Country of Origin: SECTION: 1.2 COMPANY IDENTIFICATION Company: New Directions Aromatics

amem.free.fr

LE MEDICAMENT ET LA MALADIE D’ALZHEIMER Hervé ALLAIN Laboratoire de Pharmacologie Expérimentale et Clinique _____________________________________________________________________ I – INTRODUCTION V – INDICATIONS II – OBJECTIFS DU TRAITEMENT VI – PHARMACOVIGILANCE III – PHARMACOLOGIE CLINIQUE VII – CONCLUSION IV – LES MEDICAMENTS VIII - REFERENCES

Copyright © 2010-2014 Medicament Inoculation Pdf